647
Views
38
CrossRef citations to date
0
Altmetric
Research Article

Extended-spectrum β-lactamase (ESBL) in Danish clinical isolates of Escherichia coli and Klebsiella pneumoniae: Prevalence, β-lactamase distribution, phylogroups, and co-resistance

, , , , , , , & show all
Pages 174-181 | Received 07 Apr 2011, Accepted 10 Oct 2011, Published online: 26 Feb 2012
 

Abstract

Background: Most Gram-negative community-acquired and nosocomial infections are caused by Escherichia coli and Klebsiella pneumoniae, among which increasing resistance due to extended-spectrum β-lactamase (ESBL) is a major problem. We present data from the first Danish nationwide prevalence study on ESBL-producing E. coli, K. pneumoniae, and Proteus mirabilis in blood and urine cultures from hospitals and the community. Methods: During September and October 2007, 13 of 15 Danish departments of clinical microbiology collected data and strains. Confirmatory ESBL test-positive isolates were sent to a central laboratory for species and ESBL-phenotype confirmation, extended susceptibility testing, phylogenetic grouping of E. coli strains, and ESBL gene characterization. Results: During the study, blood samples from 18,259 patients and urine samples from 47,504 patients were subjected to culture. Among 14,674 cultured isolates, 352 were confirmed to be ESBL-producers. Thus, the crude ESBL prevalence was 2.4% (range 1.5% of E. coli in community urine to 6.6% of K. pneumoniae in hospital urine). An average of 7.2 ESBL-producers per 100,000 consumed bed-days was calculated. Of the 352 reported ESBL-producers, 205 E. coli, 73 K. pneumoniae, and 1 P. mirabilis, were available for testing. CTX-M enzymes dominated, both in hospitals and in the community, occurring in 92% of E. coli and 88% of K. pneumoniae, and with CTX-M-15 constituting 60% and 77%, respectively. Conclusions: Compared to 2003 data the ESBL prevalence in Denmark has increased significantly. In the ESBL-producers, reduced susceptibility towards both gentamicin and ciprofloxacin was seen among 43% E. coli and 55% K. pneumoniae, leaving clinicians in these cases with only a carbapenem for the treatment of serious infections. Part of this study was presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases, abstract P-1617.

Acknowledgements

The following members of the DANRES Study Group, all from departments of clinical microbiology, are thanked for providing data and isolates: Kurt Fuursted, Skejby Hospital; Tove Højbjerg, Aalborg Hospital; Jens Kjølseth Møller, Vejle Hospital; Jørgen Prag, Viborg Hospital; Magnus Arpi, Herlev Hospital; Kjeld Truberg Jensen, Esbjerg Hospital; Bent Røder, Slagelse Hospital, Ole Heltberg, Næstved Hospital. H. Hasman, DTU, Copenhagen, and D. Sandvang, SSI, Copenhagen are thanked for providing control strains.

Declaration of interest: None to declare.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 174.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.